Lilly’s Abemaciclib Efficacy Data At ASCO Could Hold Up To Accelerated Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Data presented by Eli Lilly at ASCO could support accelerated approval of abemaciclib but a tolerability issue could impact its competitive position in the commercial market versus Pfizer’s Ibrance.